These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 26891628)

  • 1. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
    Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
    BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
    Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
    Gynecol Oncol; 2024 May; 184():132-138. PubMed ID: 38309030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
    de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
    PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
    Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
    Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
    Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
    Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
    Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
    Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
    Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
    Pasanen A; Loukovaara M; Tuomi T; Bützow R
    Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis.
    Geels YP; Pijnenborg JM; van den Berg-van Erp SH; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Obstet Gynecol; 2012 Nov; 120(5):1124-31. PubMed ID: 23090531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.
    Abdel Azim S; Sprung S; Mutz-Dehbalaie I; Fessler S; Zeimet AG; Marth C
    Int J Gynecol Pathol; 2017 Jul; 36(4):356-363. PubMed ID: 28221216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
    Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
    Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.